Chronic pancreatitis can cause diabetes mellitus through direct pancreatic damage — a condition known as pancreatogenic diabetes. This protocol covers the specific subgroup of patients who are not insulin-dependent and present with either insulin resistance or a preserved (normal) insulin secretory capacity.
Patients with chronic pancreatitis who have developed diabetes mellitus secondary to chronic pancreatitis, are not requiring insulin, and have evidence of insulin resistance or maintained insulin secretory capacity.
The structured regimen centres on oral hypoglycemic agents selected according to the patient's underlying metabolic profile — the complete protocol specifies which agents apply and under what conditions.
Full agent selection, sequencing, and clinical considerations are available in the complete protocol below.
DOI: 10.1007/s00535-022-01911-6
Oral hypoglycemic agents are recommended for pancreatogenic diabetes whether the patient has insulin resistance or normal insulin secretory capacity.
Although there is not sufficient evidence supporting the efficacy of oral hypoglycemic agents for pancreatogenic diabetes, medication for insulin resistance and insulin secretagogues may be effective if insulin resistance is suspected or insulin secretory capacity is maintained.
View source ↗